Navigation Links
Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
Date:6/6/2011

SUNNYVALE, Calif., June 6, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced data from the oral presentation of the Phase IB/II study of the Btk inhibitor, PCI-32765, in chronic lymphocytic leukemia / small cell lymphocytic lymphoma (CLL/SLL) at the 2011 American Society of Clinical Oncology Annual Meeting. The company will also provide a clinical development program update for the Btk Inhibitor, PCI-32765.  The update will include 1) efficacy from the Phase IA trial of PCI-32765 in B-cell malignancies including mantle cell lymphoma, follicular lymphoma and diffuse large B-cell lymphoma and 2) a status update for ongoing PCI-32765 clinical studies, and 3) an update on future clinical trials including program expansion opportunities in follicular lymphoma and multiple myeloma.  The company will also provide information on the Non-Hodgkins Lymphoma (NHL) market. An investor conference call to discuss the clinical trial results and other company updates will be hosted today at 4:30pm ET, further information is provided below.  Slide presentations will be posted on the Pharmacyclics website including the ASCO presentation of the Phase IB/II study results and the Investor Relations presentation.  

Data Results from the Phase IB/II Study in CLL/SLL as presented at ASCO

The oral presentation, titled "Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SLL): Interim results of a Phase Ib/II study" was being presented by John C. Byrd, MD today.  The presentation included interim data from a single-agent, multi-cohort study evaluating PCI-32765 in CLL/SLL patients with relapsed/ refractory disease or with treatment-naive disease who were 65 years of age or older.  A daily oral dose of 420mg was tested
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2, 2015   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... developing breakthrough treatments for human disease, will release its ... Wednesday, March 4, 2015 before the financial markets open.  ... to discuss clinical development progress and financial results for ... 10:00 a.m. Eastern Time on March 4, 2015. ...
(Date:3/2/2015)... 2, 2015  BioMed Realty Trust, Inc. (NYSE: ... 313,000 square feet of space in the most dynamic ... world through the termination of Vertex Pharmaceuticals, leases on ... effective February 28, 2015. BioMed Realty will receive a ... begin to reposition the properties to meet the growing ...
(Date:3/2/2015)... , Abbott Diabetes Care, American Association ... Corp., Apple, Arkray, Asante Solutions, A. Menarini, ... CareFusion, Carewell Biotech, Centres for Medicare and ... Center for Disease Control and Prevention (CDC), ... Pharmaceuticals, Chugai, Conceptus, Covidien, Cygnus, ConvaTec, Constitution ...
Breaking Medicine Technology:Lexicon To Report Fourth Quarter And Year End 2014 Financial Results On March 4, 2015 2BioMed Realty Gets Back 313,000 Square Feet Of Valuable Real Estate In Cambridge Innovation District 2BioMed Realty Gets Back 313,000 Square Feet Of Valuable Real Estate In Cambridge Innovation District 3Blood Glucose Meters Industry 2019 Forecasts for Global and Chinese Regions 2
... and create healthy, pain-free habitsBERKELEY, Calif., May 18 ... The Intelligent Body(R) TMJ Program as ... DIY-series of movement reeducation lessons available on CD. ... inexpensive and effective self-care method to help reduce chronic ...
... Novexel, a speciality pharmaceutical,company focused on the ... the significant global problem of microbial resistance,announces that ... NXL103 are,the subject of four posters at the ... (ECCMID). The ECCMID conference is,taking place in Helsinki ...
Cached Medicine Technology:Feldenkrais(R) Movement Institute Announces Simple Non-Surgical Solutions for Jaw and Facial Pain (TMJ) 2Feldenkrais(R) Movement Institute Announces Simple Non-Surgical Solutions for Jaw and Facial Pain (TMJ) 3Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki 2Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki 3
(Date:3/2/2015)... March 02, 2015 Atlantic Information Services, ... AIS’s Directory of Health Plans: 2015 , the ... on the U.S. health plan market, with enrollment data ... United States. , Available as a printed book ... enrollment trends in quick-view tables and charts, as well ...
(Date:3/2/2015)... La Quinta, CA (PRWEB) March 02, 2015 ... All Trades”—Jack Eadon, leader of the 1960s cult rock band ... is fueled by his determination to persevere despite all odds. ... Make It,” no matter what situation or goal was before ... of the ’60s, is now being passed on to a ...
(Date:3/2/2015)... 02, 2015 The Alliance for Bangladesh ... expert Mark Chubb to serve as chief safety officer. ... and training in Bangladesh and guide remediation efforts in ... “Mark will ensure that the Alliance continues to bring ... for Bangladesh garment workers,” said Alliance Independent Chair Ellen ...
(Date:3/2/2015)... 2015 Éminence Organic Skin Care, the ... excited to announce the launch of the Balance Collection, ... time-saving solution for those with combination skin. The Balancing ... divided jar to separate the products, consists of the ... Balancing Moisturizer Duo, also in a divided jar, contains ...
(Date:3/1/2015)... Clearwater, Florida (PRWEB) March 02, 2015 ... market their services and manage their practices ... offer an integrated all-inclusive solution. The ... development program and a medical practice management ... success and long-term financial sustainability. A referral ...
Breaking Medicine News(10 mins):Health News:Now Available from AIS: 12th Edition of Annual Book Containing Health Plan Enrollment Data, Contact Information 2Health News:Cult Rock Star’s “Got To Make It” Attitude Inspires New Generations 2Health News:Cult Rock Star’s “Got To Make It” Attitude Inspires New Generations 3Health News:Alliance for Bangladesh Worker Safety Names New Chief Safety Officer 2Health News:Éminence Organic Skin Care Launches Innovative Collection for Combination Skin 2Health News:Éminence Organic Skin Care Launches Innovative Collection for Combination Skin 3Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 2Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 3Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 4
... ... artificial sweetener Xylitol, consumers can help to prevent cavities. , ... Delray Beach, FL (PRWEB) July 8, 2009 -- Cavities are ... check-ups, a good way to prevent them, according to Delray Beach, Florida-based dentist Dr. Craig ...
... , TAMPA, Fla., July 7 Intelident Solutions, Inc. ("Intelident") today ... Directors of Zila, Inc. (Nasdaq: ZILA ) to acquire ... and the preferred stock for $0.48 per share, or a total ... premium for common stockholders of more than $418,000, or 10.5%, over ...
... Today, the Service Employees International Union (SEIU), which represents ... with U.S. District Court to hold the State in contempt ... workers by $2 per hour in defiance of an earlier ... feels it can simply ignore a U.S. District Court ruling," ...
... Cardinal Justin Rigali, Chairman of the U.S. Catholic Bishops, ... for human embryonic stem cell research issued yesterday by ... his statement follows: , , "In April I ... cell research, saying that under these guidelines ,federal tax ...
... associate professor of chemical and biomolecular engineering David Bruce ... (EFRC) funded with $12.5 million from the U.S. Department ... is focused on the development of new catalysts for ... sources. "The scientific research efforts of CALCD, combined ...
... , BALTIMORE, July 7 DaVita Inc. (NYSE: ... services for those diagnosed with chronic kidney disease (CKD), ... award-winning, leadership development and cultural orientation program for new ... DaVita,s commitment to teammate empowerment and engagement are former ...
Cached Medicine News:Health News:South Florida Dentist Dr. Craig Spodak Recommends Artificial Sweetener Xylitol to Help Prevent Cavities 2Health News:Intelident Solutions Proposes to Acquire Zila for $0.42 per share in Cash 2Health News:Contemptible: Governor, State Officials Defy Court Order to Stop Home Care Cuts, Says SEIU 2Health News:Cardinal Rigali Criticizes Final NIH Guidelines for Destructive Stem Cell Research 2Health News:DOE funds Clemson University clean energy research 2Health News:DaVita's Award-Winning Training Program for New Teammates Reaches Milestone With 100th DaVita Academy in Baltimore, Maryland 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: